Agoracom Blog Home

Posts Tagged ‘small cap’

VIDEO – Else Nutrition Has $30M In Cash And A $2.7 Billion Dollar Shareholder To Launch Plant Based Toddler Foods Around The World

Posted by AGORACOM-JC at 3:14 PM on Monday, October 26th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Welcome to be on the press release a production of AGORACOM in which we speak with small cap executive right after they put out important news,  with us again we’re happy to have her back Hamutal Yitzhak. co founder and CEO of Else Nutrition trades on the TSX venture on the stock symbol B. A. B. Y. baby and for our friends the U. S. under BABYF  for those of you new to the story it’s gonna be some yeah even though ELSE has been a real market Darling in 2020 this is the Israeli based award winning plant based food nutrition company a give small cap investors not to participate in this global paradigm shift towards plant based clean label foods and more than just lip service the company now has $30M in cash thanks in part to be backed by a 2.7B Hong Kong listed conglomerate that owns a proxy 11.6 percent of the company plus non dilutive rights that they led a recent 25.7M investment and their goal is to help the company signed international agreements which is great when you consider the fact that the company’s been awarded top times in 22 countries with 44 countries pending including our recently receiving a key USDA certified organic certification to launch the world’s first 100 percent plant based non dairy non soy baby formula in the US where they’re already going direct to consumer via Amazon and their own Estore as well as grocery and natural food stores thanks in part to a distribution agreement one of the biggest in the country in the industry here to talk about all that is Hamutal welcome to the show, Hey hi George how are you I’m very excited to be here with you. Well great I want to congratulate you on this recent financing that’s a fantastic achievement and let’s talk about that you know would we know the total not the total number of dollars raised what are you going to be using this war chest for these proceeds. Yet will still first of all them we plan to use proceeds mostly for sales and marketing them our digital social endeavors and social influencers and and also retail promotions in store give it is for sure I am absolutely R&D clinical studies them new product development and scale up stick we’re doing all the time and some inventory build up which is something that day as we roll out and into the retail space is going to be growing at an exponential growth rate and we are also and investing in our own production capacity for some of the ingredients which are holding our our I mean we have a certain I. D. for certain ingredients which are exclusively and manufactured for us and in certain places and we would like to take that into the company which is the most that you’re valuable precious asset of the company and of course working capital and then general corporate purposes saying on top of everything. I want to go into the specifics about you know distribution the U. S. and all that but first you know this financing was was led by your strategic investor H &H global tell us about that relationship where it sat and where it’s going. Yes so H&H backed as you said is that in Hong Kong and Hong Kong listed tech company with a market market cap of about them almost $3B and annual revenue of about 1.5B and in 2019 and I think they’re on the road to become a global leader in advanced baby and adult nutrition as I see em there through their international presence down they have grown to have and 4 brand centers in Australia China France and United States and R&D centers as well in China and France and some other countries and as you said they’ve increased their stake in that and else and we are working all together very closely and to them actually launch a product in Europe in their rankings in the friendship through their French operations which is a very strong operation in the baby and infant and space am and we are we’ve started negotiating with them also and the Chinese from but this is only very actively preliminary we’re building the strategy and that the whole the whole business plan to penetrate the Chinese cross border platform which is a very strong and robust operations that they’ve got and the Chinese market of course is a very important market for Else it actually represents half almost half of the infant and nutrition market globally. Well that’s exciting because I know you stated that from the first day that we started doing interviews together that you’ll one key part of that relationship is to help with international expansion into here for me now that you know conversations are beginning for France and China and so on that’s fantastic news and you know it just supports why they continue to lead financing rounds and maintain their racial ownership sought you know that that that alone I think speaks for itself let’s talk about the US market you officially launched your toddler. That was more on the eve calmer side can you tell us more about the U. S. launch strategy because I know you’re going direct to consumer as well as right into the physical grocery store let’s talk about the U. S. launch strategy because that’s obviously a big one as well. Yes as you probably know he already met and mentioned that we are already on line with our Estore and the Amazon store which has been open about 2 weeks ago and  At we already see a lot of traction and there have been disclosed at the sales you’ll be seeing that in them financial reports soon and so let’s let’s speak a little bit about and first of all our our marketing strategy you are go to market strategy as an overall it is an overarching asking over arching aspect so we focus on 3 target groups which we have identified while researching the north American market Ephesians the flexitarian and which are one group the allergic intolerant families and that I call them healthy progressive consumers those who really know back everything that that that there is on the reading list and they prefair at the minimalist standards that as little ingredients as possible in their foods these are 3 groups and these are at our elite doctors and we see great traction in the great acceptance of the brand in in those groups and there also are masters they keep reaching our story on social add channels to their friends and family and to have a room they can add their speaking in between one another and we’re helping them to do that and for to amplify that using a very big community of influencers and plant based parent in in the client base and parents faced with who will be promoting the brand and and they are so enthusiastic to do that even more than doing just a business with us because they’re reading start cited about having something right your friend so new that really you know enables the choice for parents which hasn’t been there for so many years yeah so they’re happy to be part of a double bonus one is obviously as influencers they’re working with you that’s great but the second point they’re promoting a product that they know is going to make a significant impact is it in toddler health so that’s a. Yeah that that’s a word that’s a win win for our for everybody. Sure it’s not a surprise go ahead go ahead yes their bonds to the rack to this brand is is more than just business it’s really emotional they’re very excited they’re kind of an impact mission to do something else to do something better for everyone and I’m sorry all emission. Yeah I did your media if you got passionate influencers are it’s hard to lose when you’ve got passion and influence behind it and it shouldn’t surprise you how Mattel right I remember that a couple months back you had done some surveys online about the product in the country before you started commercializing before we start launching you had some pretty good results there right from from surveys about how people were going to be accepting the product how likely they were to purchase correct. Absolutely we see that already in action that that we we’ve seen as 60 percent of them of the hand of those who were surveyed and it was then a representative sample of the American  parents and in the right ages as so we’ve seen 60 percent and willingness to by the brand and in whatever price they will be in in the in that actually in that S. R. P. that we’re talking about and and there was no there was no way I am how do you say that there was no flexibility and in terms of I mean if you would that have. Grease the price a little bit there they would still want to buy the product because there’s something about this sure the need is so big then there is no there’s no lab price and flexibility on that I mean there’s and a very very high and strong demand. And to get such an option in we can see that also and I’m with them celebrity influences that are and getting engaged with the brand we have. Several of them already approached us and am actually showed interest in working with us which is something quite give me one. And we already have one engage with us and which is Hilaria Baldwin the wife of Alec she’s a tier one influencer in the parenting and plant based based them she will help us yeah I mean she she approached us by searching for a better nutrition for her daughter she’s a mother of 5 and them so she’s she will be helping us through creating social media video content and that will actually highlight her findings and her journey as a plant based mother and so this is another sign of them of the traction of the vibe that you’re creating because people are really interested and even celebrities are seeing the value that we bring into that market and another thing that we’re going to do is after the elections will be launching an overarching euro campaign and am about and and else world that you’re creating which is a different world wow okay that’s good because I need to say I can’t wait till I can’t wait to see that absolutely said it’s really an exciting video it’s an it’s an animated video and that we’re working very hard on social and influential marketing channels to bring else to to the US public at work this. Well that’s also gonna pay off in what I’d like to call the real world you’ve got you’ve got social media influencers you’ll direct to consumer E. commerce Amazon but you’ve also got you know the fact of matter is we still got store shelves all across America and you need to find a way to get there and seems like you have you signed a key distribution agreement with one the largest most well regarded fresh natural organic specialty Ford food distributors in America and North America I thought that was a phenomenal. Yeah how important is this to the company. Yeah well. K. he is this is the distributor and it’s one it’s released one of the largest and most regarded and natural food and natural products distributors in North America the F. 57 years of experience in that in this space and actually this agreement to open distribution for else over they they got over 16 distribution centers across North America so this will be opening at ground breaking at this will be opening at stop thousands of store shelves in the United States where else and so. I’m actually we’re going to start rolling out with them from the vendor and and they’re gonna start Making that our products from 2 and distribution centers in California and Oregon right and they’ve got like are above 5000 employees in North America and they’re serving potentially for US 30000 retail outlets so just think about the potential and growing into that am. So this is this is really asking for Else in them it’s means that our products will soon be available to customers at their favorite stores across America and it’s it’s really it marks a major step in distribution and we are thrilled to be working with the real leader in natural food distribution I think that also serves as another indication of third party validation it’s very important because it’s one thing for ham Italian sack and her team to come on say we got this great product is the best product and world but you’ve got multi food conglomerates out of Hong Kong you’ve got the biggest some of the biggest distributors in North America who are participating with you and that you know they they just don’t do that unless with their expertise they’ve already determined right that the you’ve got a great product so I think that’s fantastic. Validation that we also we already see and I mean there is a great and acceptance it with them so many retailers that we’ve already are in talks with me it’s just an underpriced this through them and not through them some of them are not through them but it’s all coming from our and you know from the retail brokers that we are engaged we have 5 regal brokers and even gave an asset right you a few months ago but then there started working so now they have the distributor so we’re all set to start really rolling out immediately and we we can already see that happening with so many changes that we are talking to alright. Yeah you got your supply chain totally lined up right now metallic. Production inventorydelivery all that’s already read it I know it is but be good for going on to just gonna reaffirm that referring we at we are we just I mean we have announced and that we have that already and produced a second and a second manufacturing that run which was 3 times in volume it’s was produced successfully it’s currently being packed in them so and and the other at the next run he’s already booked them for November so we’re really rolling out and those things we are all set and we are preparing for the growth so everything is going to be in place once we need that. Give us an indication now is you’ve got all your ducks in a row you got supply chain lined up you got funding lined up you’ve got the distribution agreements lined up you got everything lined up what is rolled out to you very much fact that that the the the key he is started distributing November through California Oregon distribution centers take us through what may be the next I know 6 to 12 months looks like in terms of continue roll out with them and your other disturbed is good we’re all forget about them they’re also very sick of instructors you know do you have any sense of it I don’t want to pin you down in numbers but do you have any sense for what the rollout would look like over the next 6 to 12 months across North America. So excited first and foremost will be rolling out into more and more retailers which is news in itself it’s it’s the most exciting news and for investors to know that we are expanding and we are selling more and more  of course the awareness of the brand will be much larger as our neighbors and our and. And in marketing will grow of course after this M. financing round if you can afford a much stronger and spend in marketing your at we’ll be announcing them of course material listings Hey and with the larger nationwide retailers as they happen. And there will be several new product launches in the kid’s space and then the baby space and as well as new territories graduations and with aging age and independently at we will start the pathway of clinical delegating some of some of them I can say miraculous life changing impacts that we already see with else while that’s saying a lot while we’ve seen indications and saying it’s only indications is only incidence with certain consumers and which currently are very few but these things are really happening that parents are scared testifying about healing effects that else has. Parents are saying that they were there children were healed from P. C. mask from allergies they are starting to gain weight with not not being able to do so at with other formulations that that they were using and they’ve used everything that was there so things like that needs to be validated and we’re starting to and consider a clinical pathway to validate that. So this is something we’re going to do in the next months and needless to say we we there are long term processes that take place in the company which their immediate and outcomes are not seen now but they’re always in progress and they will eventually have a great impact on the company’s performance I’m referring to the processes such as that you know them that breakthrough plant based clean label infant formula for babies that from 0 to 12 months for example or things that we’re developing without contrition there are things that are longer term and they’re taking that they would take more than a year or even 2 years but these things are on the go I mean we are doing that we are on the pathway and this is something that investors don’t necessarily see or get the notion off so it’s important to mention that am. So I think more or less this these are the things that we we can anticipate in the next in the next coming months well that’s good that’s a great pipeline of things that’s a that’s a fantastic in person I know it’s not around the corner but I can’t wait for the adult versions of of your products you know I’m Greek a traditional meat and potatoes eater my most of my life but I’m starting to really see the value of all plant based clean nutrition eating and I would I don’t know what to wear to look quite frankly I don’t know what to trust but I know that I can trust products coming out about so at about so I can’t I can’t wait to see you guys launch that surely I can tell you that sometimes when I forget to order my my lunch in the office I just definitely be Else that colder and just drink it and it’s so full of energy and he brings me to a and gives it a completely different day when I when I’m on that diet. So I just can tell you from my own my own experience that I can recommend that will you be having distribution obviously the like Canadians who are watching this as well we know that you’re going to be going after U. S. market will it be in Canada soon as for the north American just return description you S. for now yes it is shipped to Canada from Amazon I mean not present from our Estore well working on and possibility that each will be shipped to Canada from the Amazon.com store but we don’t comply to the Canadian regulation in terms it’s just a matter of that changing some vitamins and minerals we have to create a different formulation right another run at different run for the Canadian market which is something to consider to do but first we wanted to focus on bringing the product into the U. S. market and that was that you know focus focus focus always focus so we wanted to do that and now we’re we’re creating additional protections for additional jurisdictions service Canadian is on that you know is on the table it’s not yet there we’re working on the European French formulation yeah those are bigger populations right Candice still small market relative to where you’re going after. In terms of which what how big is the markets we are dressing cell but absolutely we are very confident that about the fact that our many of our investors are Canadian we’re a Canadian company says it’s in our hearts and we are working to bring a Canadian firm relation as soon as possible back with that you know with the limitations of what the company can do at a certain time and. And don’t worry about that in the meantime the Canadian the Canadian audience will grow with the company as investors and eventually and when you get there they’ll grow physically with the company as well from from a product point of view and haven’t talked to make this considerations in terms of that you know the profitability and the yeah and to do this prioritization for themselves as well. That this is something that I’m sure that they want to congratulations I think god’s fair to say I speak on behalf of everybody when I congratulate you and your team we know that’s a big team effort over there for sure when you know we’re not just saying that as an empty platitude but big congratulations I feel a lot of pride for the fact that we’re partnered with you but I’m sure that I speak on behalf of everyone and and how you and your team to develop this company from us financial security point of view from a product point of view and now distribution point of view and what it sounds like you know more research and development point of you coming in the next 6 to 12 months with other territories last word to you to to speak to your shareholders. Yes I really want to thank all our shareholders and for their trust and for their faith and then in plant based that in in general and in Else and specifically are particularly and I can tell you that we are doing it again and saying that again we are doing our utmost to make this company a great success on a global scale and we have a wonderful team that works days and nights for that purpose we are really driven with our mission and I think it’s the most important thing because we’re not just doing business with changing thought something for the best work for the benefit of children and and and and babies in this world and they are the next generation and they they deserve better so here here we are. Well that’s a great thing about these videos will and that that is that the passion your passion really comes through here whereas a lot of companies will want to talk about just the numbers and just deal maybe their stock price something like that it’s clear how passionate you are about the space about the product about helping families parents toddlers and eventually big people but it really comes through. Thank you so much for joining us today I know you’ve got a lot of your plate we all know you do with the fact you take the time out like this is deeply appreciated. Thank you so much he was always it’s always a pleasure to talk to you and this was that like that again thank you well one of these days with the travel restrictions are done I guarantee I’ll be flying out to Israel will be doing it in person from the offices give everyone a great a great you know personal interactive experience with you but thank you thank you so much. mail out of that else products that’s what I need if that’s what needs to happen to get the old products all flights to and I’ll do whatever that’s how valuable they are yeah absolutely okay. Everyone at home you’ve been watching or if you listen via podcast how Hamutal Yitzhak ico founder and CEO of else nutrition the company trades on the TSX venture exchange on the stock symbol B. A. B. Y. now you know the relevance of that stock symbol if you didn’t know before because you knew the story and for our friends the US under B. A. B. Y.F after what’s left for you to do now if you haven’t already done it is your due diligence get to the agora com hauled for else nutrition take a look at the profile page because we know there’s a lot of information consumer this a disruptive companies in the food nutrition space and yelled new investors won’t understand everything the company is doing just to watching one video so get to the profile read through there to really get a grasp of it watch a couple videos I saw I have strongly recommend that we’ve already done with Hamutal and then make sure you get over their site to complete your due diligence and hopefully you discover your next great small cap company thanks for joining have one have a fantastic day the next time.

St-Georges $SX.ca Has Secured the Ownership of All Mineral Licenses in the Republic of Iceland $NNX.ca $OM.ca $ICM.ca

Posted by AGORACOM at 10:10 AM on Monday, October 26th, 2020
  • Completed the acquisition of Melmi EHF, the Icelandic corporation that owned the majority interest in the Thor Gold Project
  • Acquisition allows St-Georges to control its destiny and plan its exploration campaigns with no interference

Reykjavik – TheNewswire – October 26, 2020 St-Georges Eco-Mining Corp. (CSE:SX) (CNSX:SX.CN)(OTC:SXOOF) (FSE:85G1) is pleased to report that it has completed the acquisition of Melmi EHF, the Icelandic corporation that owned the majority interest in the Thor Gold Project and the remainder or the Icelandic mineral licenses not already controlled by St-Georges.

This transformative acquisition gives total control over the mineral licenses of the Republic of Iceland to St-Georges, making it the only junior exploration company to own all the mineral rights of a western country. This acquisition allows St-Georges to control its destiny and plan its exploration campaigns with no interference. It also gives the Company’s geological team access to extensive libraries of geological data, a large number of historical mineral samples and a well-maintained and secured national core shack that will be useable for future development. Furthermore, all the diamond drill cores from the Thor Gold project are now in the Company’s ownership and possession. The Company expects to be able to resample these cores in the process of elaborating its maiden NI 43-101 Gold-Silver and Copper resource estimate on the Thor Gold Project.

The Melmi EHF Acquisition

As previously disclosed in a press release on July 2, the Corporation will pay up to CA$775,000 in consideration of all the Melmi EHF shares as follows:

  1. (i)pay $65,000 upon the execution of the definitive share purchase agreement (the “Definitive Agreement”)
  2. (ii)pay an additional $60,000 on the earlier of: (a) 90 days of execution of the Definitive Agreement; and (b) the start of drilling on the Thor Gold Project;
  3. (iii)issue $400,000 of non-transferable debentures of the Corporation bearing a 6% annual interest, maturing 3 years from issuance (the “Maturity Date”), of $100,000 will be convertible into common shares in the capital of SX (the “SX Shares”) at a deemed price of $0.10 per SX Shares, $150,000 at a deemed price of $0.15 per SX Shares, and $150,000 at a deemed price of $0.20 per SX Shares; and
  4. (iv) as additional consideration, subject to and upon all the Licences Application having been granted, issue $250,000 non-transferable debentures of SX bearing a 6% annual interest, maturing 3 years from issuance, and convertible into SX Shares at a deemed price of $0.20 per SX Shares.

Iceland Operational Update

In September, the Corporation drilled a reversed circulation (RC) drill hole for a total length of 124 meters.

In October, reconnaissance and follow-up fieldwork was conducted in Vopnafjordur (Vopna) and Trollaskagi (Trolla) projects. Mineralization bearing outcrops were identified and sampled and brought to St-Georges’ secure facilities in Reykjavik for petrographic analysis. Some of the

se samples were prepared to be sent for assays to ALS Laboratories in Dublin, Ireland. Management expects that the results of these essays will become available later this year, and the Company expects to report on it as soon as the information becomes available.

Picture 1, Outcrop on Trolla Gold Project

Picture 2. Outcrop on Trolla Gold Project

Picture 3. Close up of a Quartz Vein from an Outcrop on Trolla

Picture 4 & 5: Quartz Vein from Trolla Outcrop (Picture 3) Under Magnifying glass (10X)

Picture 5. Magnified Quartz vein from Trolla Outcrop gold is associated with pyrite in Iceland

Picture 6. Outcrop at Trolla Gold Project

Picture 7. Water Stream over Outcrop at Vopna Gold.

About Iceland

Iceland climate, location, access and infrastructure (Histed,R,2010)

Located in the North Atlantic, approximately midway between Greenland and Great Britain, the warm North Atlantic Current ensures that the climate in Iceland, described as subpolar, oceanic, has generally higher temperatures than locations of similar latitude throughout the world. Regions or places that have similar climate are Tierra del Fuego, the Aleutian Islands and Alaskan Peninsula. Although Iceland lies close to the Arctic, its coasts remain ice-free year-round.

As can be expected, the southern coast is generally warmer, wetter and windier than the northern coast. The lower-lying, inland areas in the north are the most arid, although snowfall in the north during the winter months is greater than in the south.

Historically, recorded temperature extremes for the country are 30.5 C and -38.0C. The high in Reykjavik was 26.2C in 2008, and the low there was -24.5C in 1918. Although the Icelandic climate can be harsh, the GI-Melmi JV completed a drilling program at Thormodsdalur (Thor Gold Project) from November 2005 through May 2006 without undue difficulty. In the north, the increased snowfall would make an effort such as this more difficult. Reconnaissance is to be limited to the summer months.

Iceland’s infrastructure is well developed and modern. Road construction was begun around the start of the 20th century and peaked during the 1980’s. The roads are well constructed and maintained asphalt, although some gravel roads are still found. The current road system connects most of the larger towns and villages and is mostly confined to the coastal areas. Currently, there are a total of 12,691 kilometers of roads in Iceland that includes 3,262 kilometers of paved surface. Inland road access diminishes to dirt roads to no roads making access to some areas difficult, requiring foot travel or helicopter support. There are no railroads in Iceland.

Geological Setting

Iceland occurs at the junction of two large physical structures; the Mid Atlantic Ridge and the Greenland-Iceland-Faeroes Ridge (Figure 9). At this intersection, the mantle is hotter and less dense than the surrounding mantle. The mantle material rises as a result of heat and chemical-related density differences resulting in a dome in the crust above. This hotspot is causing a higher rate of extrusive volcanism at this point on the Mid Atlantic Ridge, which has, in turn, caused the region to be built up to a level more than 3 kilometers above the surrounding seafloor and covers an area of more than 350,000 km2. This is known as the Iceland Basalt Plateau. The portion of the plateau above sea level is now the country of Iceland (Martin, et al., 2007).

Tectonic Setting

In the Mid Atlantic Rift environment, the central portions of Iceland have moved outwards, away from the zones of active rifting and crustal development such that oldest rocks occur towards the margins and youngest in the center. Due to the migration of the hotspot to the south-east with time, an asymmetry has been imparted to the shape of the island. Currently, the hotspot lies under the south-eastern quadrant of the island (Corbett, 2004). This area now denotes the zone of active rifting and volcanism. Figure 10 shows the geology of Iceland defined by tectonic zones that coincide with the ages of the rocks.

Principal Tectonic Zones

The significant rift systems that have focused volcanism through time are noted below.

  • – The Snaefellsnes-Skagi Rift Zone in western Iceland was active in the 16-6.5 m.y. period. – The Reykjanes-Langjokull Rift Zone in central western Iceland resulted in the development of the Reykjanes Peninsula from about 6 my. – The North Volcanic Rift Zone became active from 3-4 my and extends to the present time. – An Eastern Volcanic Rift Zone is developing at this time.

Significant quantities of felsic intrusive and extrusive rocks occur in the dominantly basaltic sequence, and the felsic rocks locally display gold-anomalous hydrothermal alteration (Corbett, 2004).

Structurally, NE fractures reflect the spreading centre direction and are, therefore, some of the most numerous and laterally extensive fracture patterns, commonly evident as normal faults that may be exploited by dykes. NS and ENE fractures are developed as conjugate fractures during the NW-SE extension.

ImagineAR $IP.ca $IPNFF Announces Andrew Beranbom, CEO & Founder of First Tube Media, as Advisor to CEO to Launch Immersive AR Live Music Streaming Activations $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 7:16 AM on Monday, October 26th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Announced that Andrew Beranbom has joined the Company as an Advisor to the CEO for the purpose of launching Immersive AR Engagement during Live Streaming Branded Music Concerts
  • Mr. Beranbom is the CEO & Founder of First Tube Media with current clients including GrubHub, St. Jude’s Hospital and Tito’s Vodka
  • ImagineAR believes Mr. Beranbom will significantly accelerate the Company’s presence and revenue in Live Streaming Branded Music Concerts.

VANCOUVER, BC and ERIE, Pa. , Oct. 26, 2020 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality Company that enables sports teams, brands and businesses to instantly create their own mobile phone AR campaigns, is pleased to announce that Andrew Beranbom has joined the Company as an Advisor to the CEO for the purpose of launching Immersive AR Engagement during Live Streaming Branded Music Concert s .  Mr. Beranbom is the CEO & Founder of First Tube Media with current clients including GrubHub, St. Jude’s Hospital and Tito’s Vodka.  ImagineAR believes Mr. Beranbom will significantly accelerate the Company’s presence and revenue in Live Streaming Branded Music Concerts.

Andrew Beranbom said; “ImagineAR is the most advanced AR platform in the market today and I am excited to have the opportunity to dig in deeper into their innovative capabilities and leverage the platform to bring next gen engagement experiences for brands.  With the explosion of livestream creation and consumer behavior it is an exciting time to think through the next phase of innovation around consumer engagement and how to bring in the 2 nd screen to live media experiences and create demonstrable ROI.

Since the pandemic started, First Tube Media has executed over 50+ brand owned exclusive livestreams with companies including Grubhub, Northwell Health, MasterCard, Chase, CDW, Tito’s Vodka creating must watch “tune in moments” that have engaged over 60 million fans via a variety of premier artists from Camila Cabello , Questlove, Meghan Trainor and just over the past 6 weeks most recently 3 #1 Billboard artists Morgan Wallen , Ian Diorr and 24kGolden.

“Andrew is a forward-thinking entrepreneur and truly understands the enormous potential of integrating Augmented Reality for Brand Sponsored Live Streaming Events to drive engagement,” said Alen Paul Silverrstieen, CEO and President of Imagine AR. “With today’s paradigm shift in digital live experiences, Mobile Augmented Reality is a perfect engagement technology to compliment First Tube Media’s innovative digital live experiences and drive revenue.”

This press release is available on the Company’s AGORACOM Discussion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About First Tube Media

First Tube Media brings the live industry together to create must-watch live cultural moments. Its platform enables talent, event creators and sponsors to find each other and connect via a full-service approach operating premium live stream creation and proprietary distribution services that deliver endless online exposure and clear ROI. The company is a full-service team of music industry experts, film makers, digital marketing experts, and software developers creating Tune-In worthy branded live content distributed and optimized for ROI. Clients Include GrubHub, Tito’s Vodka, MasterCard, Northwell Health and St. Jude’s Hospital. www.firsttubemedia.com

About ImagineAR

ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO

(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if Imagine AR Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward- looking information is based on certain key expectations and assumptions made by Imagination Park’s management. Although Imagine AR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Imagine AR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and Imagine AR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Seven virtual and augmented reality #AR application areas boosted by global #5G deployment – SPONSOR: Imagine AR $IP.ca $IPNFF $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 8:30 PM on Sunday, October 25th, 2020

SPONSOR: Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) is an Augmented Reality platform that allows businesses to easily launch AR campaigns. Clients Include: NBA Sacramento Kings, Mall of America, AT&T Shape and The Basketball Hall of Fame. ImagineAR and NFL Alumni Academy recently signed a 5 year partnership agreement. In addition, the company signed a two-year agreement with Valencia C.F. of La Liga to provide interactive Augmented Reality experiences for almost 7 million fans around the world. Learn More.

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Seven virtual and augmented reality application areas boosted by global 5G deployment

By CM Staff

SANTA CLARA, Calif. — Frost & Sullivan’s recent analysis, Empowering the Future of VR/AR Content Consumption through 5G, covers seven virtual reality (VR)/augmented reality (AR) application areas and their use cases.

The market overview includes the education and training industries, public sector, automotive, manufacturing/engineering and robotics, healthcare, retail and hospitality, and gaming and entertainment. It also highlights the challenges and barriers to industry-wide VR/AR adoption and finds that the use cases for VR and AR across sectors will increase significantly with the growth in global 5G deployments.

“Although the adoption of VR/AR technology outside gaming and entertainment is still in its infancy, immediate work needs to be done to establish the use cases and vision for VR/AR and develop solutions to disrupt the predicted spaces,” said Melody Siefken, information & communication technologies research analyst, in a prepared statement. “Countries at the forefront of 5G deployments are the United States, South Korea, and China, with other countries catching up with either mobile or fixed wireless access to 5G.” Siefken added: “There is an optimistic push for 5G deployments to cater to the rising demand for bandwidth and the need for faster networking speed. With the COVID-19 crisis, there has been a slowdown in the supply chain that could delay 5G deployments, which could ultimately impact the use cases of AR/VR.”

According to Frost & Sullivan’s research, market participants should focus on the following industries to capitalize on immense growth prospects:

  • Education and training: AR/VR could enable remote training and distance learning to create engaging classroom content that accomplishes the same objectives as in-person schooling.
  • Healthcare: Virtual therapy, vital health monitoring and the opportunity to create platforms for training and exploration are benefits of using AR/VR in healthcare.
  • Automotive: Aside from driver assistance and customer experience, there are many emerging application areas for VR in the automotive industry. For instance, VR can provide an alternative to new vehicle test-driving, which is safer and cheaper as it eliminates the need for additional vehicles for test driving.
  • Manufacturing, Engineering and Robotics: The manufacturing industry is being disrupted by the use of VR and AR in design, prototyping, production, prevention of workplace hazards, inventory management, training, and assembly.
  • Public Sector: AR/VR can enhance emergency management, smart cities and defense programs. Disaster preparedness, real-time information overlay, and personnel training are some of the application areas in the public sector.

Read More: https://www.canadianmanufacturing.com/technology/seven-virtual-and-augmented-reality-application-areas-boosted-by-global-5g-deployment-262688/

VIDEO – Else Nutrition $BABY.ca Has $30M In Cash And A $2.7 Billion Dollar Shareholder To Launch Plant Based Toddler Foods Around The World $BABYF $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 8:29 PM on Sunday, October 25th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

When a $2.7 Billion Dollar Hong Kong listed, Nutrition Focused company holds 11.6% of your stock, agrees to a voluntary 12-month lock up, holds anti-dilution rights to maintain it’s ownership percentage and leads your latest $25,000,000 + financing, it is safe to assume you have a strategic investor who believes in the future of your company.  

When that same strategic investor wants to then help your company expand into large international markets, beginning with France and China, it is safe to assume your plant based food capabilities are amongst the most respected in the world. 

This is just a glimpse into the strength of Else Nutrition (BABY:TSXV) (BABYF:OTCQB), an Israeli based, award winning plant based food nutrition company that is giving small cap investors an opportunity to participate in the global paradigm shift towards plant-based, clean label foods. 

BUT THERE IS MORE

  • Else has a $30,000,000 war chest for a US product launch that is commencing here in Q4
  • US product launch will include store shelves with multiple distributors including  one of the largest fresh, natural organic and specialty food distributors in North America
  • US product launch also includes direct to consumer through Amazon and Else e-commerce site.
  • Global plans are supported by patents in 22 countries, with another 44 countries pending.  
  • Else developed the world’s first 100% plant based, non-dairy, non-soy baby formula
  • Pre-launch surveys show extremely high purchase intentions from target market.

Given all of these achievements, it should come as no surprise that Else Nutrition is made up of Executives & Advisors from globally renowned companies and institutions.

If you believe in the future of plant-based, clean label foods or want to discover its possibilities, then watch this great interview with Hamutal Yitzhak, the CEO and Co-Founder of Else Nutrition who discusses the company’s current strengths and plans for global expansion in this very fast moving market. 

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Plant-Based Products Aren’t Just a Trend, They’re Here to Stay – Else Nutrition $BABY.ca $BABYF $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 11:40 AM on Friday, October 23rd, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Else Nutrition Brings Plant-Based Products to the Infant Nutrition Space

  • Demand for plant-based foods extends far beyond just burgers
  • One of the companies that has moved to fill a previously unserved segment of the plant-based food market is Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQX:BABYF), an Israel-based food and nutrition company focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults.
  • The company’s flagship product is a non-soy, non-dairy plant-based infant nutrition formula. Else Nutrition celebrated its US product launch in August with products now available in retail stores and online.

NEW YORK, Oct. 23, 2020 – Over the past few years, plant-based meat and dairy substitutes have gone from a niche product to a major segment in the food industry. Now, these products are increasingly available just about everywhere you look in the food industry. Plant-based options are now available not just in your local grocery store but at your local pub and fast food joint. Plant-based products are now being offered by a wider range of brands from recently IPO’d startups to international giants. These products are also working their way into a wide range of subcategories in the food market, including infant nutrition and diet foods. In the wake of smash plant-based hits like Impossible Foods, companies like Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQX:BABYF) and Forum Merger II (NASDAQ:FMCI) are finding unserved niches in the market, while established food companies like Tyson Foods (NYSE:TSN), ConAgra Brands (NYSE:CAG), and Kellogg (NYSE:K) play catch-up.

Else Nutrition Brings Plant-Based Products to the Infant Nutrition Space

Demand for plant-based foods extends far beyond just burgers. One of the companies that has moved to fill a previously unserved segment of the plant-based food market is Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQX:BABYF), an Israel-based food and nutrition company focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. The company’s flagship product is a non-soy, non-dairy plant-based infant nutrition formula. Else Nutrition celebrated its US product launch in August with products now available in retail stores and online.

On September 24, Else Nutrition announced that the company had made its products available to US consumers on Amazon.com. The move makes Else’s products available to more consumers than ever via the world’s largest e-commerce platform. Direct-to-consumer online sales are a cornerstone of Else’s go-to-market strategy, particularly as the ongoing global pandemic has driven up demand for products available via delivery. Additionally, Else Nutrition is also pushing to expand its presence in grocery and health food stores. The company announced on August 20 that it had hired a specialized broker to help bring their products to one of the US’s largest retail chains.

Else Nutrition announced on October 13 that Health and Happiness (H&H) International Holdings Limited, a global health and wellness company and a leading infant nutrition player in China, had increased its investment in the company by C$4.0 million. The private placement, which was previously announced on September 15, now totals C$25.7 million. Else Nutrition plans to use the funds to accelerate and increase its production and supply capabilities, marketing activities, and product development.

Companies Move into the Plant-Based Foods Market

Tyson Foods (NYSE:TSN), the largest meat company in the United States, announced in June that it would be moving into the plant-based meat alternative market. The company announced its new Raised & Rooted brand, which will sell plant-based and mixed meat/plant products. Tyson Foods, with its already massive consumer reach, says it expects plant-based foods to be a billion-dollar business for the company.

ConAgra Brands (NYSE:CAG), the parent company for brands like Orville Redenbacher, Hunts, and Duncan Hines, has been selling meat-free products through its Gardein brand since 2009, but as plant-based meat substitutes have surged in the market, the company is updating its offerings. On September 23, ConAgra announced a line of Gardein soups featuring plant-based meat alternatives.

Kellogg (NYSE:K) got in on the plant-based trend with its Incogmeato line of products. The company is focusing on products aimed at families and young children. To that end, Kellogg announced on September 17 that the company would be partnering with Disney for its latest plant-based offering, Mickey Mouse-branded “Chick’n” Nuggets.

On October 15, holding company Forum Merger II (NASDAQ:FMCI) announced a partnership with plant-based food company Ittella International to form the Tattooed Chef brand. Tattooed Chef will focus on a wide range of meatless foods, some of which will include plant-based meat alternatives. 

Plant-based alternatives to meat are the biggest trend in the food industry in years, and the marketplace is filling up fast. Companies like Else Nutrition are positioning themselves within specific, previously unserved segments of the food industry to ensure that they can become the main plant-based players in that space.

For more information about Else Nutrition, click here.

DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above. MSC owns and operates Streetsignals.com.  References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Else Nutrition Holdings.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

Media Contact:
FN Media Group, LLC
[email protected]
+1(561)325-8757

Innocan Pharma $INNO.ca Announces the Publication of Two Studies Supporting Its CLX Therapy for COVID-19 Infected Lung Cells $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 7:35 AM on Friday, October 23rd, 2020
Innocan-Blog
  • Announced the recent publication of two scientific articles supporting Innocan’s approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19
  • The first paper entitled, “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients” published in the Journal of Stem Cell Research & Therapy on October 15, 2020
  • study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors
  • The second paper entitled, “Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome” published in the Journal of Cellular and Molecular Medicine on October 15, 2020
  • Demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms

Herzliya, Israel and Calgary, Alberta–(October 23, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce the recent publication of two scientific articles supporting Innocan’s approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19. The first paper entitled, “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients” published in the Journal of Stem Cell Research & Therapy on October 15, 2020 outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19. Specifically, the study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors.

The second paper entitled, “Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome” published in the Journal of Cellular and Molecular Medicine on October 15, 2020, demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms (which is a physiological reaction in humans and other animals in which the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines) caused by COVID-19.

Innocan Israel, a wholly owned subsidiary of the Company, together with Tel Aviv University Prof. Daniel Offen and his team, are developing a revolutionary combined therapy using MSC-driven Exosome-based loaded with CBD. The new combination is designed to target COVID-19 and neurodegenerative diseases.

Through their potential synergistic anti-inflammatory effect, CBD-Loaded Exosomes hold the potential of helping the body fight against the COVID-19 virus’s direct damage and its cytokine storm. This product is planned to act as a “guided missile” to the infected tissues, as the Exosomes migrate to Inflamed zones that are carrying CBD.

Prof. Offen added: “The recent publications which support our unique approach is exciting. The potential synergistic effect of CBD and Exosomes is of great potential for COVID-19 and other diseases known for local inflammation that causes destruction. We are doing our best efforts to accelerate the development and to potentially offer a new approach for the COVID-19 treatment”.

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Coronavirus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable

Empower Clinics $CBDT.ca Enters Canadian Market with Proposed Acquisition That Includes 6 Clinics and Incentives to Open Additional 30 Clinics and Announces Private Placement of Up to $1.1 Million $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 5:14 PM on Wednesday, October 21st, 2020
  • Announced it has entered into a non-binding term sheet to acquire the businesses of Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc dba Atkinson, and Momentum Health Inc. collectively (“Momentum Health“).
  • Momentum Health operates a network of medical clinics with a comprehensive team of physicians and therapists who apply a holistic and hands on approach working with patients to unlock potential well-being.
  • 6 clinics in greater Toronto area with plans to expand
  • Closing will be conditional upon, amongst other customary items listed below, Empower completing a debt or equity financing to raise minimum gross proceeds of $750,000 CAD
  • To this end, the Company has entered into an agreement with Mackie Research Capital Corporation in connection with a best efforts, private placement for gross proceeds of up to $1,100,000, the details of which are outlined below
  • The private placement is scheduled to close on or about the week of November 2, 2020.

Acquisition Expands Company’s North American Footprint And Strengthens Vertical Integration From Patients To Laboratory

VANCOUVER, BC / October 21, 2020 / Empower Clinics (CSE:CBDT)(OTC PINK:EPWCF)(FRA:8EC) (the “Company” or “Empower“), a vertically integrated health and wellness company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and a world-class medical diagnostics laboratory, is pleased to announce it has entered into a non-binding term sheet to acquire the businesses of Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc dba Atkinson, and Momentum Health Inc. collectively (“Momentum Health“).

Closing will be conditional upon, amongst other customary items listed below, Empower completing a debt or equity financing to raise minimum gross proceeds of $750,000 CAD. To this end, the Company has entered into an agreement with Mackie Research Capital Corporation in connection with a best efforts, private placement for gross proceeds of up to $1,100,000, the details of which are outlined below. The private placement is scheduled to close on or about the week of November 2, 2020.

Closing of the acquisition is expected to occur on or about November 10, 2020.

6 CLINICS IN GREATER TORONTO AREA WITH PLANS TO EXPAND MODEL ACROSS CANADA

Momentum Health operates a network of medical clinics with a comprehensive team of physicians and therapists who apply a holistic and hands on approach working with patients to unlock potential well-being. Key services include Physiotherapy, Chiropractic, Massage Therapy, Traditional Chinese Medicine, Athletic Therapy and others.

The proposed acquisition will include the acquisition of two standalone wellness clinics and four new co-located clinics in the Greater Toronto area of Ontario, Canada. Moreover, the proposed acquisition includes incentives for the two Co-Founders of Momentum Health to open an additional 30 clinics across Canada.

Steven McAuley, Chairman and CEO of Empower Clinics stated, “The acquisition of Momentum Health is expected to advance the direction and growth prospects for Empower overall,” said Steven McAuley, Empowers Chairman & CEO. “As we continue to position Empower as an integrated healthcare company, bringing alternative care together with primary care facilities enables us to deploy a better healthcare model, based on progressive technology and in-person care. Having Dr. Rabinowitz and Dr. Tsimerman join me in leadership to rapidly expand Empowers clinic footprint across Canada is another important step toward our growth objectives.”

Momentum Health Co-Founder Dr. Rabinowitz commented “Our core values of professionalism, corporate responsibility and community health fall directly in line with Empower. We are extremely excited to collaborate with this tremendous organization to provide reliable and trusted healthcare for communities across Canada.”

Momentum Health Co-Founder Dr. Tsimerman commented “Momentum Health has always stood on the foundations of providing an unparalleled patient experience and bridging the gap between the conventional medical system and paramedical services.”

PROPOSED TERMS OF ACQUISITION

Under the proposed terms, the Company will pay $275,000 CAD cash at closing and a $75,000 CAD performance holdback, for an aggregate cash payment of $350,000 CAD. In addition, at closing, Empower will issue Dr. Jordan Rabinowitz and Dr. Aviv Tsimerman common shares in the capital of Empower (“Shares“) having an aggregate value of $250,000 CAD and, subject to the satisfaction of defined performance metrics, additional Shares having an aggregate value of $250,000 CAD, which will vest in quarterly installments over 24 months following the closing. All Share consideration is expected to be based on a deemed price per Share equal to the 10-day volume weighted average closing price per Share on the Canadian Securities Exchange (the “CSE“) for the period ending on the last business day prior to the closing.

PERFORMANCE INCENTIVES TO OPEN 30 ADDITIONAL LOCATIONS

The proposed acquisition also includes long-term performance incentives that upon achieving the opening of:

Ten (10) new clinic locations (“Milestone One”) the issuance to the Vendors subject to terms and conditions as set out in the Stock Option Plan, an irrevocable option (the “Share Option“) to purchase at any time or from time to time on or before the Expiration Date, 1,250,000 Shares of the Corporation.

Twenty (20) new clinic locations (“Milestone Two”) the issuance to the Vendors subject to terms and conditions as set out in the Stock Option Plan, an irrevocable Share Option to purchase at any time or from time to time on or before the Expiration Date, 1,250,000 Shares of the Corporation.

Thirty (30) new clinic locations (“Milestone Three”) the issuance to the Vendors subject to terms and conditions as set out in the Stock Option Plan, an irrevocable Share Option to purchase at any time or from time to time on or before the Expiration Date, 1,250,000 Shares of the Corporation.

All issuances will be at a deemed price per Share equal to the 10-day volume weighted average closing price per Share on the CSE for the period ending on the last business day prior to the achievement of Milestone One, Two or Three.

ADDITIONAL DETAILS

The proposed consideration assumes a debt free transaction and will be adjusted accordingly for any level of debt assumed by the Company, directly or indirectly. The transaction is expected to be structured on a tax efficient basis, and otherwise in accordance with the requirements of requisite securities laws and the policies of the CSE.

Empower has agreed to enter into employment agreements with Dr. Rabinowitz and Dr. Tsimerman, to lead the proposed Canadian clinic expansion strategy.

Completion of the transaction includes Momentum Health interests in certain affiliates and will be subject to various conditions, including entry into a definitive agreement, completion of due diligence, and receipt of all required shareholder, manager, third party and regulatory approvals, including approval of the CSE.

PRIVATE PLACEMENT

The Company is also pleased to announce that it has entered into an agreement with Mackie Research Capital Corporation, as sole agent and sole bookrunner (the “Agent“), in connection with a best efforts, private placement of units of the Company (the “Units“) at a price of $0.05 per Unit (the “Offering Price“) for gross proceeds of up to $1,100,000 (the “Offering“).

Each Unit will be comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“). Each Warrant shall be exercisable to acquire one Common Share (a “Warrant Share“) at a price of $0.12 per Warrant Share for a period of 24 months from the closing of the Offering.

The Agent will have an option (the “Agent’s Option“) to offer for sale up to an additional 15% of the number of Units sold in the Offering at the Offering Price, which Agent’s Option is exercisable, in whole or in part, at any time up to 48 hours prior to the closing of the Offering.

The Company intends to use the proceeds raised under the Offering to support the development of clinics through clinic acquisitions, lab testing services, sales and marketing, for general working capital purposes.

The securities to be issued under the Offering will be offered by way of private placement in each of the provinces of Canada, and such other jurisdictions as may be determined by the Company, in each case, pursuant to applicable exemptions from the prospectus requirements under applicable securities laws.

The Offering is scheduled to close on or about the week of November 2, 2020, or such date as agreed upon between the Company and Agent (the “Closing“) and Closing of the Offering may occur in multiple tranches, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Canadian Securities Exchange. The Units to be issued under the Offering will have a hold period of four months and one day from Closing.

In connection with the Offering, the Agent will receive an aggregate cash fee equal to 8.0% of the gross proceeds from the Offering, including in respect of any exercise of the Agent’s Option. In addition, the Company will grant the Agent, on date of Closing, non-transferable compensation options (the “Compensation Options“) equal to 8.0% of the total number of Units sold under the Offering (including in respect of any exercise of the Agent’s Option). Each Compensation Option will entitle the holder thereof to purchase one Unit at an exercise price equal to the Offering Price for a period of 24 months following the Closing.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Momentum Health acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

ImagineAR $IP.ca $IPNFF Announces First-Ever WebAR Retail Project in North America $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 7:15 AM on Wednesday, October 21st, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Announced its first-ever mobile WebAR Retail Project launching in December 2020
  • New product offering for ImagineAR and first commercial agreement to provide ‘non-app’ augmented reality experiences for a major retail campaign program using 3D models
  • Consumers will experience augmented reality using their mobile phone cameras without downloading an app in a retail environment

VANCOUVER, BC and ERIE, Pa. , Oct. 21, 2020 – ImagineAR (IP:CSE) (IPNFF:OTCQB) an Augmented Reality Company that enables businesses to instantly create their own mobile phone AR campaigns, is pleased to announce its first-ever mobile WebAR Retail Project launching in December 2020.  This is a new product offering for ImagineAR and first commercial agreement to provide ‘non-app’ augmented reality experiences for a major retail campaign program using 3D models. Consumers will experience augmented reality using their mobile phone cameras without downloading an app in a retail environment.

According to Statista, The WebAR Global Marketplace is expected to reach $198 Billion USD by 2025.

“This is a major milestone for ImagineAR to deliver a WebAR retail experience revenue project”, said Alen Paul Silverrstieen, CEO of ImagineAR.  “This will be a keystone AR campaign and we expect it to create new prospects and client opportunities in today’s challenging Covid-19 environment.”

Imagine AR Signs Middle East Reseller

WeStirItUp, headquartered in Dubai , is a hybrid agency focused on delivering services in the field of sports activations, fan engagement and experiential marketing. The executive team has over 50 years of combined experience servicing blue chip global clients including Reckitt Benkiser, Huawei, Dubai Sports Council and a host of other international/local brands covering, FMCG, eCommerce, Consumer durables, Automobile and global sporting bodies.

“WeStirItUp is excited to partner with ImagineAR and introduce its superlative mobile AR platform solutions to the Middle East , African and Indian marketplace. Today’s market demands experiential campaigns that have an improved consumer engagement and therefore resulting in higher ROI. AR definitely has its edge as one advanced innovative tech that helps brands create sticky content and deeper engagement”, stated Divya Rajan , Founder Director at WeStirItUp, “and we are excited to work with ImagineAR to expand their global client base in 2020, she added.

This press release is available on the Company’s AGORACOM Discussion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About ImagineAR

ImagineAR Inc. (IP:CSE) (IPNFF: OTCQB) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies. ImagineAR is available as an SDK to be integrated into existing mobile apps.

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO

(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if Imagine AR Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward-looking information is based on certain key expectations and assumptions made by Imagine AR management. Although Imagine AR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Imagine AR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and Imagine AR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Innocan Pharma’s $INNO.ca Clinical Study in the US Indicates that More than 90% of Participants Experienced Pain Reduction After Using Innocan’s Relief &Go OTC Pain Relief Spray $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:11 PM on Monday, October 19th, 2020
Innocan-Blog
  • Study indicates that more than 90 % of participants experienced reduction in pain after using Innocan’s Relief & Go OTC Pain Relief Spray
  • The clinical study was conducted on 18 participants: 10 participants with chronic pain and 8 participants with pain associated with other circumstances
  • Most participants described their pain before using the spray as throbbing and uncomfortable and a few described their pain as distressing

Herzliya, Israel and Calgary, Alberta–(October 19, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today a Clinical Study, conducted by Dr. Josef Geldwert and the Center for Podiatric Care & Sports Medicine in New York. The study indicates that more than 90 % of participants experienced reduction in pain after using Innocan’s Relief & Go OTC Pain Relief Spray. The clinical study was conducted on 18 participants: 10 participants with chronic pain and 8 participants with pain associated with other circumstances. Most participants described their pain before using the spray as throbbing and uncomfortable and a few described their pain as distressing. The location of the pain varied from the upper extremities of the back to the lower extremities and feet.

After 20 minutes 83% of participants noticed immediate improvement in pain.
After 60
 minutes 95% of participants noted relief from pain.
After 24 hours almost 90%
 noted relief from pain.

15 of the 18 participants would recommend the Relief and GO pain spray.


Relief and GO Pain Spray

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/66309_f493f3f5d4ab1931_002full.jpg

The Center for Podiatric Care & Sports Medicine in New York specializes in treating chronic problems resulting from sports injuries and active lifestyles.

Dr. Josef Geldwert has over 40 years of experience in foot surgery, biomechanics, and sports injuries. In addition, he has been a medical authority to numerous professional sports teams.

In addition, Dr. Geldwert serves as advisor on Innocan Pharma’s Scientific Advisory committee.

Innocan Pharma’s Relief & Go Pain Relief Spray is a patent pending Over-The-Counter solution designed to relieve pain by combing three different mechanisms in one product: Menthol and Methyl salicylate with CBD and Magnesium.

Dr. Josef Geldwert stated, “I have been following up with patients who I have been seeing for foot and ankle related problems that have been using Relief and Go Pain Relief Spray, and their responses have been positive. I am impressed by how well patients have been doing with a non-prescriptive OTC pain relief spray.”

“We are thrilled that our clinical test yielded such promising results,” says Ms. Iris Bincovich, Chief Executive Officer of Innocan, “Our unique approach and deep experience is exemplified in these impressive results that I’m certain are only the beginning.”

About Innocan

Innocan Israel, a wholly owned subsidiary of the Company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable